metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Últimos avances en tumores de páncreas
Journal Information
Vol. 35. Issue S1.
Jornada de Actualización en Gastroenterología Aplicada
Pages 91-97 (September 2012)
Share
Share
Download PDF
More article options
Vol. 35. Issue S1.
Jornada de Actualización en Gastroenterología Aplicada
Pages 91-97 (September 2012)
Full text access
Últimos avances en tumores de páncreas
Latest advances in pancreatic tumors
Visits
11777
Julio Iglesias-García
Corresponding author
julio.iglesias.garcia@sergas.es

Autor para correspondencia.
, J. Enrique Domínguez-Muñoz
Servicio de Aparato Digestivo, Fundación para la Investigación en Enfermedades del Aparato Digestivo (FIENAD), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, España
This item has received
Article information
Resumen

El cáncer de páncreas (CP) es una enfermedad de difícil diagnóstico y tratamiento. Su pronóstico es ominoso, ya que suele detectarse en fases avanzadas, cuando la posibilidad de cualquier tratamiento curativo no es mayor del 20%. Con la idea de mejorar el pronóstico se están desarrollando las nuevas pautas en las estrategias de cribado, sobre todo con el desarrollo de un nuevo consenso internacional con recomendaciones sobre el manejo de pacientes con alto riesgo de desarrollar un CP. En la línea de mejorar el diagnóstico se confirman la elastografía y los contrastes guiados por ultrasonografía endoscópica (USE) como 2 tecnologías especialmente útiles en este contexto. También hay avances en la punción guiada por USE, con el desarrollo de agujas de histología que aumentan la eficacia diagnóstica y la calidad de las muestras. Finalmente, pocos avances en el tratamiento, confirmándose el papel límite de la neoadyuvancia en tumores localmente avanzados, la eficacia de diferentes estrategias de neurólisis para el tratamiento del dolor, y para el tratamiento de la obstrucción biliar las prótesis metálicas recubiertas parecen ser la mejor opción. Sobre los tumores quísticos de páncreas destacar el desarrollo de la endomicroscopia confocal guiada por USE para mejorar su diagnóstico y la optimización de las estrategias de seguimiento, sobre todo del tumor mucinoso papilar intraductal de rama lateral.

Palabras clave:
Cáncer de páncreas
Tumor quístico de páncreas
Cribado
Diagnóstico
Abstract

Pancreatic cancer is difficult to diagnose and treat. Prognosis is poor, since this disease is usually detected at advanced stages, when the possibilities of any treatment with curative intent are 20% or less. To improve prognosis, new screening strategies are being designed, especially with the development of a new international consensus with recommendations on the management of patients at high risk of developing pancreatic cancer.

Two especially useful techniques in the diagnosis of this disease are elastography and contrast-enhanced endoscopic ultrasound (EUS). Advances have been made in EUS-guided biopsy with the development of histology needles that increase diagnostic efficacy and the quality of the samples. Finally, there have been a few advances in treatment. The role of neoadjuvant therapy in locally advanced tumors and the efficacy of distinct neurolysis strategies in pain therapy have been confirmed. Covered metallic stents seem to be the best option to treat biliary obstruction. A notable development is the development of EUS-guided confocal endomicroscopy to improve the diagnosis and follow-up of cystic tumors of the pancreas, especially intraductal papillary mucinous tumors of the lateral branch.

Keywords:
Pancreatic cancer
Cystic tumor of the pancreas
Screening
Diagnosis
Full text is only aviable in PDF
Bibliografía
[1.]
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, et al.
Cancer statistics, 2008.
CA Cancer J Clin, 58 (2008), pp. 71-96
[2.]
D. Li, K. Xie, R. Wolff, J.L. Abbruzzese.
Pancreatic cancer.
Lancet, 363 (2004), pp. 1049-1057
[3.]
J. Iglesias-García, J. Lariño-Noia, J.E. Domínguez-Muñoz.
Early diagnosis of pancreatic cancer, time tos creen high-risk individuals?.
Minerva Gastroenterol Dietol, 57 (2011), pp. 205-212
[4.]
M.I. Canto, F. Harinck, R.H. Hruban, J. Offerhaus, J.W. Poley, P. Fockens, et al.
International Consensous Recommendations on the Management of patients with increased risk for familial pancreatic cáncer: Cancer of the Pancreas Screening Consortium (CAPS) 2011 Summit.
Gastroenterology, 142 (2012), pp. S135
[5.]
A.L. Lucas, R. Shakya, M. Lipsyc, E.B. Mitchel, S. Kumar, C. Hwang, et al.
Demonstration of a high frequency of BRCA1 and BRCA2 germiline mutatoins with loss of heterozygosity: a series of resected pancreatic adenocarcinomas and other preneoplastic lesions.
Gastroenterology, 142 (2012), pp. S509
[6.]
F. Hanrinck, S.E. Korsse, M.G. Van Lier, K. Biermann, J. Offerhaus, N. Krak, et al.
Pancreatic cancer risk in Peutz-Jeghers patients; results of a large dutch cohort study and implications for surveillance.
Gastroenterology, 142 (2012), pp. S622
[7.]
A. Sud, M.F. Catalano, D. Wham, N.M. Gude.
More evidence supporting genetic counseling and testing followed by endoscopic ultrasounf in the early detection od pancreatic cáncer in high risk patients.
Gastroenterology, 142 (2012), pp. S616
[8.]
S. Kumar, S. Amin, C. Hwang, E.C. Verna, J. Chua, E.B. Mitchel, et al.
Interval follow-up of high risk pancreatic cancer screening patients demonstrates no significant lesions within one year.
Gastroenterology, 142 (2012), pp. S512
[9.]
J. Iglesias García, J. Larino Noia, J.E. Domínguez Muñoz.
Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer.
Rev Esp Enferm Dig, 101 (2009), pp. 631-638
[10.]
J. Iglesias-García, B. Lindkvist, J. Larino-Noia, J.E. Domínguez-Muñoz.
The role of EUS in relation to other imaging modalities in the differential diagnosis between mass forming chronic pancreatitis, autoimmune pancreatitis and ductal pancreatic adenocarcinoma.
Rev Esp Enferm Dig, 104 (2012), pp. 315-321
[11.]
J. Iglesias-García, J.E. Domínguez-Muñoz.
Endoscopic ultrasound image enhancement elastography.
Gastrointest Endosc Clin N Am, 22 (2012), pp. 333-348
[12.]
M. Kitano, H. Sakamoto, M. Kudo.
Endoscopic ultrasound: contrast enhancement.
Gastrointest Endosc Clin N Am, 22 (2012), pp. 349-358
[13.]
A.M. Ortiz, S. Elhanafi, R. McCallum, M.J. Zuckerman, M.O. Othman.
The diagnostic accuracy of endoscopic ultrasound (EUS) elastography in differentiating benign from malignant pancreatic lesiones, a meta-analysis.
Gastrointest Endosc, 75 (2012), pp. AB181-AB182
[14.]
S.A. Andrawes, P. Hindy, Y. Taur, N. Anand, L.S. Deeb, F.G. Gress.
Accuracy of endoscopic elastography for detection of malignant pancreatic mass lesions. Systematic review and meta-analysis.
Gastrointest Endosc, 75 (2012), pp. AB207
[15.]
D.I. Gheonea, C.T. Streba, A.N. Ioncica, T. Ciurea, A. Saftoiu.
Diagnosis of focal pancreatic masses by quantitative low mechanical index constrast enhanced endoscopic ultrasound (EUS).
Gastrointest Endosc, 75 (2012), pp. AB205
[16.]
M. Fukusawa, S. Takano, M. Kadokura, E. Takahashi, T. Sato, N. Enomoto.
Quantitative perfusion analysis of contrast-enhanced harmonic endoscopic ultrasonograhy in solid lesions of the pancreas.
Gastrointest Endosc, 75 (2012), pp. AB132
[17.]
J. Iglesias-García, B. Lindkvist, J.B. Cruz-Soares, L. Lopes, C. MarraLópez, J. Lariño-Noia, et al.
Differential diagnosis of solid pancreatic masses. Contrast-enhanced harmonic endoscopic ultrasound, quantitative-elastography endoscopic ultrasound or both?.
Gastrointest Endosc, 75 (2012), pp. AB147
[18.]
M.A. Eloubeidi, S. Varadarajulu, S. Desai, R. Shirley, M.J. Heslin, M. Mehra, et al.
A prospective evaluation of an algorithm incorporating routine preoperative endoscopic ultrasound-guided fine needle aspiration in suspected pancreatic cancer.
J Gastrointest Surg, 11 (2007), pp. 813-819
[19.]
R. Suzuki, M.S. Bhutani, S. Ramireddy, S.G. Krishna, B.R. Weston, W.A. Ross, et al.
The diagnostic value of repeat endoscopic ultrasound-guided fine needle aspiration for solid pancreatic lesions: a tertiary referral center experience.
Gastrointest Endosc, 75 (2012), pp. AB199
[20.]
W. Wang, A. Shpaner, S.G. Krishna, W.A. Ross, M.S. Bhutani, E.P. Tamm, et al.
Utilization of EUS-FNA in diagnosis¡ng pancreatic neoplasm without definitive masses on CT scans.
Gastroenterology, 142 (2012), pp. S22
[21.]
V. Eguia, M. Winner, A. Sethi, J.M. Poneros, C.J. Lightdale, J.D. Allendorf, et al.
Preoperative EUS-FNA does not adversely affect outcomes in resectable pancreatic cancer.
Gastrointest Endosc, 75 (2012), pp. AB194
[22.]
J. Iglesias-García, J.W. Poley, A. Larghi, M. Giovannini, M.C. Petrone, I. Abdulkader, et al.
Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study.
Gastrointest Endosc, 73 (2011), pp. 1189-1196
[23.]
M.C. Petrone, P.G. Arcidiacono, M.J. Bruno, M. Giovannini, J. Iglesias- García, A. Larghi, et al.
Comparison between EUS-guided 19G and 22G procore needle biopsies in pancreatic masses: a prospective multicenter study in 72 cases.
Gastrointest Endosc, 75 (2012), pp. AB195
[24.]
T. Iwashita, Y. Nakai, J.B. Samarasena, D.H. Park, J.G. Lee, K.J. Chang.
High single-pass diagnostic yield (cytology and histology) of a novel 25-gauge core biopsy for EUS-guided fine needle aspiration and bioosy in pancreatic solic lesions.
Gastrointest Endosc, 75 (2012), pp. AB192-AB193
[25.]
V. Mehendiratta, J. Lewis, J. Korenblit, A. Infantolino, R.M. Cobem, M. Bibbo, et al.
Prospective comparative study of the EUS-guided 22-gauge Cook Procore; FNA needle with the 22-gauge Cook Echo Tip needle in patients with solid mass lesions.
Gastrointest Endosc, 75 (2012), pp. AB191-AB192
[26.]
S. Varadarajulu, J.Y. Bang, J. Ramesh, J. Trevino, S. Hebert-Megee.
Randomized trial comparing the biopsy and asppiration needles for EUS-guided sampling of solid pancreatic masses.
Gastrointest Endosc, 75 (2012), pp. AB190
[27.]
J. Iglesias-García, I. Abdulkader, J. Lariño-Noia, J.E. Domínguez-Muñoz.
Differential diagnosis of solid pancreatic masses: Do procore histology needles improve the diagnostic yield of standard cytology needles?.
Gastrointest Endosc, 75 (2012), pp. AB203
[28.]
S. Wani, A. Wang-Gillam, D.S. Early, P. Kim, D. Mullady, F. Murad, et al.
Comparison of phosphorylation signatures in patients with suspected pancreatic cancer undergoing EUS-FNA with and without malignant cytology: a pilot study.
Gastrointest Endosc, 75 (2012), pp. AB189-AB190
[29.]
S. Wani, A. Wang-Gillam, D.S. Early, P. Kim, D. Mullady, F. Murad, et al.
Evaluation of phosphorylation signatures in suspected pancreatic cancer using EUS-FNA aspirates: A feasibility study.
Gastroenterology, 142 (2012), pp. S533
[30.]
M. Hidalgo.
Pancreatic cancer.
N Engl J Med, 362 (2010), pp. 1605-1617
[31.]
J.C. Ardengh, R. Kemp, E.R. Lima, C.G. Bertani, G.A. Mota, J.S. Dos Santos.
A prospective controlled trial of the EUS-CPN bilateral injection of 30 cc of alcohol in patients with pancreatic cancer pain.
Gastrointest Endosc, 75 (2012), pp. AB432
[32.]
H. Sakamoto, M. Kitano, M. Kudo.
A prospective feasibility study on EUS brosad plexus in combination of celiac ganglion neurolysis in pancreatic cancer pain.
Gastrointest Endosc, 75 (2012), pp. AB442
[33.]
V. Dudeja, S.P. Walker, E.W. Greeno, E.H. Jensen.
Neoadjuvant chemoradiotheraoy for locallu¡y advanced pancreas cancer does not lead to radiologic tumor regression.
Gastroenterology, 142 (2012), pp. S1100
[34.]
S. Satoi, H. Toyokawa, H. Yanagimoto, T. Yamamoto, S. Hirooka, S. Yamaki, et al.
Neoadjuvant chemoradiation therapy using S-1 for patients with pancreatic cancer.
Gastroenterology, 142 (2012), pp. S1097-S1098
[35.]
M. Kitano, K. Yamashita, K. Tanaka, H. Konishi, S. Yazumi, Y. Nakai, et al.
Drastic improvement of patency of covered self-expandable metal stents for distal obstruction caused by pancreatic carcinomas: a randomized multicenter study comparing covered and uncovered stents.
Gastrointest. Endosc, 75 (2012), pp. AB123
[36.]
K. Kubota, T. Sato, S. Kato, S. Watanabe, K. Hosono, N. Kobayashi, et al.
Covered self-expandable metal stent deployement promises safe neoadjuvant chemotherapy in patients with borderline resectable pancreatic head cancer.
Gastrointest Endosc, 75 (2012), pp. AB305-AB306
[37.]
K. Kim, E.J. Tryggestad, A.T. Wild, M.A. Ziegler, E.J. Shin, R.Z. Sharaiha, et al.
Comparative analysis of traditional and viscoil fiducials implanted during endoscopic ultrasound for pancreatic cancer patients receiving stereotactic body radiation therapy.
Gastrointest Endosc, 75 (2012), pp. AB190
[38.]
M. Gaidhane, I.B. Smith, K. Ellen, J.J. Gatesman, N. Habib, P.L. Foley, et al.
Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) of the páncreas in a porcine model: a novel palliative option?.
Gastroint Endosc, 75 (2012), pp. AB193
[39.]
K. De Jong, M.J. Bruno, P. Fockens.
Epidemiology, diagnosis, and management of cystic lesions of the pancreas.
Gastroenterol Res Pract, 2012 (2012), pp. 147465
[40.]
M. Tanaka, C. Fernández-del Castillo, V. Adsay, S. Chari, M. Falconi, J.Y. Jang, et al.
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.
Pancreatology, 12 (2012), pp. 183-197
[41.]
Y. Nakai, T. Iwashita, D.H. Park, J.B. Samarasena, J.G. Lee, K.J. Chang.
Diagnosis of pancretic cysts: endoscopic ultrasound, throughthe- channel confocal laser-induced endomicroscopy and cystoscopy trial (Detect Study).
Gastrointest Endosc, 75 (2012), pp. AB145-AB146
[42.]
V.J. Konda, A. Meining, L.H. Jamil, M. Giovannini, K.J. Chang, J.H. Hwang, et al.
An International, multicenter trial on needle-based confocal laser endomicroscopy (nCLE): Results from the in vivo CLE Study in the páncreas with endosonography of cystic tumors (INSPECT).
Gastrointest Endosc, 75 (2012), pp. AB188-AB189
[43.]
J. Lariño-Noia, J. Iglesias-García, M. Macías, A. Martín, M. Legaz, P. Rendon, et al.
A muticenter, prospective, comparative, randomized open trial of endoscopic ultrasound cytology brushing vs fine-needle aspiration (FNA) for the pathological diagnosis of cystic pancreatic lesions.
Gastrointest Endosc, 75 (2012), pp. AB181
[44.]
J. Sreenarasimhaiah, P. Kandunoori, A. Patel, D. Agrawal.
Longterm follow-up of indeterminant pancreatic cysts initially examined by endoscopic ultrasound.
Gastrointest Endosc, 75 (2012), pp. AB132
[45.]
K. Mandai, A. Suzuki, S. Morikawa, T. Kawamura, K. Yasuda.
Risk factors for the development of pancreatic ductal adenocarcinoma during the follow-up of branch duct-tyoe intraductal papillary mucinous neoplasms of the pancreas.
Gastroenterol Res Pract, (2012), pp. 619
[46.]
N. Anand, K. Sampath, A. Fraser, B.U. Wu.
Validation of the international consensoud guidelines for brach duct intraductal papillary mucinous neoplasms of the páncreas: A meta-analysis.
Gastroenterology, 142 (2012), pp. S852-S853
Copyright © 2012. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos